Pharmaceutical giant Pfizer Inc., headquartered in New York City, has halted its $350 million manufacturing plant project in Everett. This marks a shift in the company’s expansion strategy following its acquisition of Bothell-based Seagen for $43 billion.
According to the Puget Sound Business Journal, the Everett facility at 215 Shuksan Way was originally part of Pfizer’s plan to enhance its manufacturing capabilities. In 2021, Seagen signed a lease for the 269,097-square-foot facility and Pfizer had announced intentions to construct a medical production plant on site.
However, operations and therapeutic products that were planned for production at this location will now be relocated to an existing plant in Sanford, North Carolina. As a result of this decision, approximately 120 employees will be laid off. “This is not reflective of our colleagues’ performance but rather aligns with our site capacity design to meet business needs,” stated Pfizer.
The article titled “Pfizer Abandons $350M Plant in Everett After Seagen Acquisition” was published by Connect CRE.
